Safety and Efficacy of LUMIGAN® RC Versus DuoTrav® in Patients Who Require Further Intraocular Pressure (IOP) Reduction
Status:
Completed
Trial end date:
2013-07-01
Target enrollment:
Participant gender:
Summary
This non-inferiority study will assess safety and efficacy of LUMIGAN® RC (bimatoprost
ophthalmic solution 0.01%) versus DuoTrav® (travoprost 0.004%/timolol 0.5% combination
ophthalmic solution) in patients previously on Travatan® Z (travoprost ophthalmic solution
0.004%) monotherapy.